A life-changing diagnosis

A year ago, Carrie Downie, a single mother raising a 17-year-old son, was diagnosed with colon cancer. Six months after beginning treatment with a new experimental drug, doctors delivered remarkable news — the cancer was gone, Euronews reports.

A targeted medication still in trials

The drug, called dostarlimab, is currently undergoing clinical trials. It is designed to treat a specific type of colorectal cancer caused by genetic abnormalities in tumor cells.

All patients receiving the treatment share a mutation in the mismatch repair (MMR) gene, which affects how cells repair DNA damage.

According to Swansea Bay University Health Board, this genetic defect occurs in approximately 3.5 to 5 percent of rectal cancer cases.

A future once filled with fear

Initially, the 42-year-old woman was told that surgery could leave her with a permanent stoma — a medical bag attached to the abdomen to collect waste for the rest of her life.

Seeking alternatives, Carrie was referred by the South West Wales Cancer Centre to Dr. Craig Barrington, who offered a different approach.

A new option without major surgery

After reviewing her biopsy results, Dr. Barrington confirmed that Carrie carried the rare mutation required for the treatment.

He explained that trials had already shown strong results and that funding could be secured because she met all the necessary criteria. Carrie agreed to proceed.

For six months, she received the medication intravenously three times a week. Each session lasted around 30 minutes.

Minimal side effects, dramatic results

Carrie reported feeling tired and experiencing occasional skin rashes during treatment. However, she emphasized that these effects were mild compared to chemotherapy, radiotherapy, or invasive surgery.

As the months passed, scans showed the tumor shrinking. By the end of the treatment period, doctors could no longer detect any cancer.

A medical milestone

Dr. Barrington later stated that this was the first time in the UK — and among the first cases worldwide, alongside Italy — that this treatment was used as standard clinical practice.

He noted that the drug is not mandatory for every patient but represents a powerful new option. With research showing a 100 percent response rate in selected cases, it is difficult to ignore its potential.

The case offers new hope for cancer patients who meet specific genetic criteria.